Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Advertisement
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

Canada Overhauls Drug Pricing, But Devil Will Be In The Detail

Long awaited changes to Canada’s Patented Medicines Regulations have been announced, but companies will have to wait for new guidelines from the pricing watchdog to better understand how they will be implemented.

North America Canada

Aspen Will Pay UK's NHS £8m In Landmark Deal Following Competition Probe

Aspen has agreed to pay the National Health Service £8m following an investigation by the Competition and Markets Authority.

Compliance Legal Issues

Aspen to Pay UK NHS £8m In Landmark Deal Following Competition Probe

Aspen has agreed to pay the National Health Service £8m following an investigation by the Competition and Markets Authority.

Europe United Kingdom

Biogen Taken To Task Over Spinraza Price In Belgium & Italy

Excessive pricing is once again under the spotlight In Europe. Consumer rights organizations in Belgium and Italy have referred Biogen to the national competition authorities over “exorbitant pricing.”

Europe Belgium

Australian Reform Is Opportunity For International Work-Sharing On Non-Biological Complex Drugs

Plans to streamline the approval of generic medicines in Australia must include measures to ensure that safe and effective similar versions of non-biological complex medicines are available.

Australia Asia Pacific

Australian Generics Approval Reform Is Opportunity For International Work-Sharing On Non-Biological Complex Drugs

Plans to streamline the approval of generic medicines in Australia must include measures to ensure that safe and effective similar versions of non-biological complex medicines are available.
Australia Asia Pacific
See All
Advertisement
UsernamePublicRestriction

Register